Nothing gets Singaporeans going like a hotel buffet. After all, eating is our national hobby. The only problem? The cost. Aside from atas Michelin-starred restaurants, buffets are pretty much the most ...

City Compensatory Allowance Cities with a Population of 45 lakhs and above 3% of pay, subject to a maximum of Rs ... Candidates selected for the position of LIC Assistant Administrative Officer (AAO) ...

Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial, causing the stock to plummet ~90% and trade near book value. The company's decision to discontinue other simufilam trials ...

Roche’s SKYSCRAPER-01 has fallen down. The phase 3 trial found adding the TIGIT candidate tiragolumab to Roche's approved checkpoint inhibitor had no effect on overall survival (OS) in non-small ...

Starting at RM168+ per pax, Kuang’s restaurant is tailored for groups of a minimum of 10 people and above. Diners can enjoy a thoughtfully crafted Western Christmas menu presented in either an elegant ...

Aside from other quality-of-life changes, we can expect that each phase will have the same content released during Classic’s 2019 launch. Here’s what you can expect from each of the phases on these ...

“A result like this has implications on our second Phase 3 trial, ReFocus-ALZ. We have made the difficult decision to discontinue ReFocus-ALZ, given the nature of today’s reported result ...

High-level results from the company’s ongoing CAPltello-281 phase 3 study demonstrated that a combination of Truqap, Johnson & Johnson's Zytiga and androgen deprivation therapy (ADT) delivered ...

Cassava Sciences stock fell Monday after the company shared a Phase 3 update on its Alzheimer's disease drug. "Pharma Bro" Martin Shkreli predicted the stock's fall Sunday night. Cassava Sciences ...

Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer’s disease in the ReThink-ALZ Phase 3 study Simufilam ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today positive topline results from the Phase 3 ZENITH study evaluating WINREVAIR ...

Second positive phase 3 trial adds to growing body of evidence for WINREVAIR, an activin signaling inhibitor therapy that targets an underlying cause of PAH RAHWAY, N.J., November 25, 2024 ...